The investigation into the long-term (52 weeks) effects of dupilumab-mediated IL4-Ra blockade on skin barrier impairment and immune response in elderly patients with F or NF AD is, in our opinion, an innovative approach. The gene discussed is IL4R; the disease is Alzheimer disease.